ReviewJournal of endocrinological investigation2011
Androgen regulation of prostate cancer: where are we now?
Review in Journal of endocrinological investigation, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Adult- and late-onset male hypogonadism: the clinical practice guidelines of the Italian Society of Andrology and Sexual Medicine (SIAMS) and the Italian Society of Endocrinology (SIE).Journal of endocrinological investigation · 2022Guideline
- Outcomes of androgen replacement therapy in adult male hypogonadism: recommendations from the Italian society of endocrinology.Journal of endocrinological investigation · 2015Pooled it
- Effect of metabolic syndrome and its components on prostate cancer risk: meta-analysis.Journal of endocrinological investigation · 2013Pooled it
- Prostate cancer risk and antioxidant biomarkers: the age-dependent reversal of bilirubin's role.BMC urology · 2025Article
- The role of testosterone in male sexual function.Reviews in endocrine & metabolic disorders · 2022Review
- Unravelling Prostate Cancer Heterogeneity Using Spatial Approaches to Lipidomics and Transcriptomics.Cancers · 2022Review
- MicroRNA‑195‑5p is associated with cell proliferation, migration and invasion in prostate cancer and targets MIB1.Oncology reports · 2021Article
- Article
- Cardiovascular Risks of Androgen Deprivation Therapy for Prostate Cancer.The world journal of men's health · 2021Review
- Sexual function in men undergoing androgen deprivation therapy.International journal of impotence research · 2021Review
- Correlation Between Testosterone Replacement Treatment and Lower Urinary Tract Symptoms.International neurourology journal · 2021Article
- Sexual desire of French representative prostate cancer survivors 2 years after diagnosis (the VICAN survey).Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2019Article
- Testosterone Replacement Therapy: Long-Term Safety and Efficacy.The world journal of men's health · 2017Review
- Sexual Dysfunction in Type 2 Diabetes at Diagnosis: Progression over Time and Drug and Non-Drug Correlated Factors.PloS one · 2016Observational
- Are biomarkers evaluated in biopsy specimens predictive of prostate cancer aggressiveness?Journal of cancer research and clinical oncology · 2016Article
- 5α-Reductase inhibitors increase acute coronary syndrome risk in patients with benign prostate hyperplasia.Journal of endocrinological investigation · 2015Article
- Benign prostatic hyperplasia: a new metabolic disease?Journal of endocrinological investigation · 2014Review
- Curcumin Inhibits Prostate Cancer Bone Metastasis by Up-Regulating Bone Morphogenic Protein-7Journal of cancer therapy · 2014Article
- Quality of Life and Sexual Health in the Aging of PCa Survivors.International journal of endocrinology · 2014Review
- Benign prostatic hyperplasia: a new metabolic disease of the aging male and its correlation with sexual dysfunctions.International journal of endocrinology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAndrogens play an essential role in the development and differentiation of the prostate gland; their contribution to pathological conditions, such as benign prostatic hyperplasia and prostate cancer (PC), remains unclear.
aimWe reviewed relationships between androgens and the prostate both in physiological and pathological conditions. MATERIAL AND
methodsA systematic search of published evidence was performed using Medline (1969 to September 2010).
resultsAndrogen-dependency of prostate growth is evident only in the hypogonadal condition, but not in the eugonadal state (the "saturation hypothesis"). There is unequivocal evidence that reducing androgen signaling to the hypogonadal range can reduce PC growth and patient symptoms. At physiological testosterone concentration there is no link between androgen levels and PC risk. In addition, different strategies of androgen deprivation (ADT) for advanced PC are only palliative and rarely cure patients. Preliminary evidence indicates that a low androgen milieu is associated with tumor aggressiveness. Transition to androgen-independence is complex and involves both selection and outgrowth of preexisting androgen resistant clones, as well as adaptative upregulation of genes that help the cancer cells to survive and grow after ADT. Because androgens are essential for the regulation of fat distribution, insulin sensitivity, and lipid and bone metabolism, recent publications have highlighted the concept that ADT may also be involved with an increase in overall, as well as cardiovascular, morbidity and mortality.
conclusionsWhile ADT still represents a cornerstone for the palliative therapy of a small fraction of aggressive PC, a "misuse and/or abuse" of ADT should be avoided.
Indexed as
Identifiers
21297383What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.